The complaint alleges that between January 14, 2025, and May 6, 2026, Zoetis executives failed to disclose critical information regarding the company's product performance. Specifically, the suit claims that veterinarian interest in the canine pain treatment Librela waned following FDA safety warnings about potential neurological complications. Furthermore, the filing suggests that market share for key products, including Simparica Trio, Apoquel, and Cytopoint, eroded in the face of lower-priced or newly launched competitors. Plaintiffs argue these developments rendered the company's public statements regarding its business operations materially misleading. Affected shareholders interested in participating or discussing their legal rights can contact the Law Offices of Howard G. Smith by phone at 215-638-4847 or via email.
Investors Eye Lead Role in Zoetis Securities Fraud Suit
Investors who sustained significant financial losses in Zoetis Inc. now face a July 27, 2026, deadline to seek the role of lead plaintiff in a pending class action lawsuit. The Law Offices of Howard G. Smith is currently spearheading the litigation, which centers on allegations of misleading corporate disclosures.
Comments (0)
No comments yet. Be the first!